Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy

Informazioni relative al progetto

IF-EBOla

ID dell’accordo di sovvenzione: 666102

DOI 10.3030/666102

Progetto chiuso

Data della firma CE 3 Dicembre 2014

Data di avvio 1 Novembre 2014

Data di completamento 31 Ottobre 2017

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 2 037 770,00

Contributo UE € 1 992 770,00

Coordinato da

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
France

Risultati finali

Documents, reports (3)

Ebola virus diversity assessed by sequencing

The report will provide an overview of Ebola virus diversity as assessed by sequencing necessary to optimize the diagnostic, treatment and vaccine approaches.

Whole infectious profiles

The report will provide an overview of the diversity of infectious profiles from available samples.

Ethical regulations, security and safety set up for diagnostic and follow-up of patients of the phase 1 (without treatment)

Ethical regulations set up to work with the present project for diagnostic and treatment

Websites, patent fillings, videos etc. (1)

Creation of the specific website of the project

Creation of the specific website of the project.

Pubblicazioni

Conference proceedings (11)

Metagenomic analyses and genomic fingerprint of co-infections of the EBOLA viral disease

Autori: W. Valdivia-, D. Sheoran, G. Dubois, S. Tigrett, F. Veas
Pubblicato in: 2015
Editore: Tofo conference on Filovirus, Ebola and Other Filoviruses

Development of a specific polyclonal immunoglobulin against Ebola

Autori: C. Herbreteau & IF Ebola
Pubblicato in: 2015
Editore: First World Congress on Targeting Ebola

Lessons Learned from the Development of an Ebola Immunotherapy

Autori: R Metrop, JF Saluzzo, F Veas, C. Herbreteau
Pubblicato in: 2017
Editore: IV International Conference on Mitigation Strategies for Emerging Infectious diseases

Specific polyclonal F(ab’)2immunoglobulin fragments; in vitro characterization and in vivo effectiveness in post-exposure treatment against Zaire Ebola virus in mice

Autori: M. Denizot, T. Racine, D. Pannetier, A. Pasquier, H. Raoul, JF Saluzzo, G. Kobinger, F. Veas, C. Herbreteau
Pubblicato in: 2017
Editore: The II International Conference CBRNE - Research & Innovation

Atypical immune response of EVD Long-term survivors

Autori: Y. Eskira A Sobarzo, F Veas L Lobel
Pubblicato in: 2017
Editore: VIII International Conference on Emerging Zoonoses and transboundary Infectious Diseases

The preparedness IF-EBOLA toolbox for rapid and efficient mitigation of upcoming outbreaks. A platform model for emerging diseases

Autori: F.Veas
Pubblicato in: 2016
Editore: International Conference on Mitigation Strategies for Emerging Infectious diseases

Efficiency of innovative preparedness IF-EBOLA technologies: Ultrasensitive diagnostics, horse anti-Ebola virus polyclonal Fabs & metagenomic analyses of Ebola variants and co-infections

Autori: F.Veas
Pubblicato in: 2017
Editore: IV International Conference on Mitigation Strategies for Emerging Infectious diseases

Ebola virus Genomic and Metagenomic signature Analyses of the 2014-15 West African Outbreak

Autori: W. Valdivia, D. Sheoran, & F. Veas
Pubblicato in: Numero 7th Filovirus Conference, 2015
Editore: 7th Filovirus Conference

Multi-technological platforms to solve unmet needs for rapid and efficient management of emerging diseases

Autori: F.Veas
Pubblicato in: 2015
Editore: XIX International Congress for Tropical Diseases

A Universal virus capture method leading to a rapid and ultrasensitive detection of pathogens for early & late post-exposure countermeasures

Autori: S Tigrett, L Lobel, F Veas
Pubblicato in: 2017
Editore: VIII International Conference on Emerging Zoonoses and transboundary Infectious diseases

RIGEL as a Powerful Computational Architecture for Genomic & Metagenomic Signature Discrimination: Analysis of the 2014-15 West African EBOLA Outbreak”

Autori: W. Valdivia, D. Sheoran & F. Veas
Pubblicato in: Numero Gordon Research Conferences, on Biodefense and Bioterrorism meeting, 2015, Pagina/e March 8-13, 2015
Editore: Gordon Research Conference

Other (1)

Resveratrol-Linoleate protects from exacerbated endothelial permeability via a drastic inhibition of the MMP-9 activity

Autori: A Shamseddin, C Crauste, E Durand, P Villeneuve, G Dubois, T Pavlickova, Th Durand, J. Vercauteren, and F Veas
Pubblicato in: 2018
Editore: BioScience Reports 2018

Peer reviewed articles (1)

Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions

Autori: Aly Shamseddin, Céline Crauste, Erwann Durand, Pierre Villeneuve, Gregor Dubois, Thierry Durand, Joseph Vercauteren, Francisco Veas
Pubblicato in: European Journal of Lipid Science and Technology, Numero 119/11, 2017, Pagina/e 1700171, ISSN 1438-7697
Editore: Wiley - V C H Verlag GmbbH & Co.
DOI: 10.1002/ejlt.201700171